A

Alfresa Holdings Corp
TSE:2784

Watchlist Manager
Alfresa Holdings Corp
TSE:2784
Watchlist
Price: 2 389 JPY 0.55% Market Closed
Market Cap: ¥457B

EV/EBIT

6.6
Current
1%
More Expensive
vs 3-y average of 6.5

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
6.6
=
Enterprise Value
¥278.1B
/
EBIT
¥36.7B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
6.6
=
Enterprise Value
¥278.1B
/
EBIT
¥36.7B

Valuation Scenarios

Alfresa Holdings Corp is trading above its 3-year average

If EV/EBIT returns to its 3-Year Average (6.5), the stock would be worth ¥2 361.6 (1% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-8%
Maximum Upside
+106%
Average Upside
47%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 6.6 ¥2 389
0%
3-Year Average 6.5 ¥2 361.6
-1%
5-Year Average 6.1 ¥2 194.07
-8%
Industry Average 12.7 ¥4 590.57
+92%
Country Average 13.6 ¥4 922.75
+106%

Forward EV/EBIT
Today’s price vs future ebit

Not enough data available to calculate forward EV/EBIT

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close

Market Distribution

Lower than 88% of companies in Japan
Percentile
12th
Based on 4 801 companies
12th percentile
6.6
Low
0.1 — 9.8
Typical Range
9.8 — 18.1
High
18.1 —
Distribution Statistics
Japan
Min 0.1
30th Percentile 9.8
Median 13.6
70th Percentile 18.1
Max 414 821 439

Alfresa Holdings Corp
Glance View

Market Cap
457B JPY
Industry
Health Care

In the bustling world of pharmaceuticals and healthcare, Alfresa Holdings Corp. stands as a notable player, weaving a complex web that connects various facets of the medical industry in Japan and beyond. Founded in 2003 as a result of a merger, Alfresa has carved a niche for itself in the logistics and distribution sector of pharmaceuticals. The company's core strength lies in its ability to streamline the journey of medicinal products from manufacturers to healthcare providers. This massive undertaking is facilitated by an intricate network of strategic partnerships and a robust supply chain, ensuring that pharmacies, hospitals, and clinics receive the necessary products promptly and efficiently. Alfresa’s revenue streams are as diversified as the products it handles. Beyond its role as a distributor, the company has expanded into the manufacturing of its own pharmaceuticals, further solidifying its position in the market. This vertical integration allows it not only to distribute third-party products but to add value by developing and marketing its proprietary offerings. In an industry rife with competition and regulatory challenges, such a strategy provides a dual advantage: a stable supply for its distribution networks and an additional revenue channel. Alfresa's commitment to innovation and efficiency has enabled it to maintain steady growth, balancing between its traditional distribution roots and its forays into pharmaceutical production, thus affirming its status as a key cog in the healthcare industry’s machine.

Intrinsic Value
3 968.6 JPY
Undervaluation 40%
Intrinsic Value
Price ¥2 389
A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett